Latest Breaking News On - Triple hit lymphoma - Page 1 : comparemela.com

Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy.

International prognostic indexLargeb cell lymphomaB cell lymphomaCart cell therapyLymphoma treatmentResponse rateEvent free survivalDouble hit lymphomaTriple hit lymphomaZuma 7Belinda trialTransform trialAutologous stem cell transplantFirst line therapyR chopHigh risk lymphoma

Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies

Discover cutting-edge cellular therapeutics, CAR T-cell therapy, and bispecific strategies for treating lymphoma patients in clinical trials.

Transforming largeb cell lymphomaNovel agentsLymphoma treatmentsLargeb cell lymphomaB cell lymphomaCart cell therapyLymphoma treatmentBispecific antibodiesDouble hit lymphomaTriple hit lymphomaInternational prognostic indexGenetic rearrangementsR chopCytogenetic abnormalities

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin s Lymphomas

Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication highlights in vitro and in vivo results supporting LP-284’s development for mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin s lymphoma (NHL) with immediate patient needs. Lantern is anticipating filing the IND application with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in NHL, including MCL, during the second half of 2023.

Kishor bhatiaSecurities exchangeLantern pharma incStarlight therapeutics incExchange commission onLantern pharmaBusiness wirePanna sharmaChief scientificPublication highlightsTriple hit lymphomaDrug designationLooking statementsSecurities actSecurities exchange actRisk factors

Biomea Fusion, Inc (BMEA) Reports Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219

Biomea Fusion, Inc (BMEA) Reports Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLos angelesThomas butlerExchange commissionSecurities exchangeInternational myeloma societyBiomea fusion incAnnual meetingPresentation detailsHigh gradeb cell lymphomaMultiple myeloma preclinicalDiffuse largeb cell lymphomaTriple hit lymphomaDouble expressor lymphomaSecurities actSecurities exchange act

Biomea Fusion to Present New Preclinical Data Showing BMF-219 s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

Biomea Fusion to Present New Preclinical Data Showing BMF-219 s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomas butlerVan sandwickdirectorExchange commissionAmerican society of clinical oncologyInvestor relations corporate developmentSecurities exchangeBiomea fusion incAmerican societyClinical oncologyAnnual meetingTrial in progressChief executive officerPresentation detailsSession titleHematologic malignancies